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The recommendations present the current state of knowledge on the presented subject on the day of publication.  
The board of experts reserves the right to update the information in case of new significant scientific reports.  
 
The board of experts undertook the analysis of literature, expert knowledge and clinical experience  
in matters of use of dietary supplementation in pregnancy.
INTRODUCTION
Progress in medicine allows for a better understanding 
of the purpose of dietary components in prophylaxis of 
civilization diseases and suggests that alimentation not only 
supplies energy and nutrients but provides compounds es-
sential for proper functioning of the body as well [1].
Based on every day medical practice we can conclude 
that future mothers attach relatively substantial importance 
to their diet. They realize the importance of diet and its 
impact on the condition and development of the fetus. 
It is common among pregnant women to use dietary supple-
ments, which often does not have any rational justification. 
It is estimated that about 78–98% of pregnant women in 
the USA, Canada and Australia use dietary supplements [2]. 
There are no reliable data from Poland, but observations in 
obstetrical practice let us assume that the supplementation 
trend is very similar.
In literature there are contradictory reports regarding 
the safety and effectiveness of supplementation usage by 
pregnant women. 
According to the WHO statement from 2016, as well 
as the majority of medical associations, a routine usage of 
multivitamin regimens by all pregnant women is not recom-
mended. The basic source of microelements and vitamins 
should come from a well-balanced diet. 
The following recommendations of the Polish Society of 
Gynecologists and Obstetricians present an up-to-date view 
on the importance of dietary supplementation in pregnancy 
in accordance with current knowledge and recommenda-
tions. We present five active substances — iron, folic acid, 
vitamin D, DHA acid and iodine, which are considered to 
be the basic elements useful in pregnancy supplementa-
tion. Presence of other microelements, vitamins and active 
substances in supplementation, therefore supplementing 
a normal diet is not recommended in a population of healthy 
women with no specified medical indications. 
IRON
We talk about iron balance as a resultant of two factors: 
iron intake and loss. The total amount of this element in 
adults is about 4–5 g and is mostly present as a compo-
nent of hemoglobin (75%), ferritin and hemosiderin (20%). 
In proper conditions there is a state of dynamic balance 
between the iron contained in hemoglobin and the storage 
and transport proteins. 
Outside of pregnancy, a regular diet usually fully covers 
the daily requirement for iron. It increases during pregnancy 
daily by about 1 mg in the first trimester and 7.5 mg in the 
third trimester, which is the result of an increasing demand 
of a growing fetus, placenta and an increasing volume of 
the uterine muscle [3]. Iron deficiency is the most common 
cause of anemia in pregnancy.
The lower limit of hemoglobin in pregnancy defined by 
WHO is 11 g/dL (6.8 mmol/L). Anemia in pregnancy is defined 
by the level of Hgb below 11 g/dL in every trimester of preg-
nancy according to WHO [4]. Undoubtedly, it is quite a big 
interpretive simplification, though one giving the possibility 
of applying unified and proper treatment. When analyzing 
the necessity of iron supplementation, it is more useful to 
divide the normal range for hemoglobin depending on the 
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trimester of pregnancy. CDC runs a simplified scheme of such 
range considering Hgb concentration < 11 g/dL in I and III 
trimester and Hgb < 10.5 g/dL in II trimester as reference 
ranges for diagnosing anemia in pregnancy [2, 5–7].
In „The Global Prevalence of Anemia in 2011” report, 
WHO states that in Europe anemia occurs in about 20–40% 
of all pregnant women aged 15–49, and it simultaneously 
recommends iron supplementation of all pregnant and 
planning pregnancy women, 30–60 mg daily to reduce the 
risk of perinatal complications, infections, low birth weight 
and preterm births. 
The majority of scientific societies (Royal College of Ob-
stetrics and Gynaecology (RCOG), Royal Australian and New 
Zealand College of Obstetrics and Gynaecology (RANZCOG), 
European Food Safety Authority (EFSA), Scientific Advisory 
Committee on Nutrition (SACN), British Society for Haema-
tology, Obstetric Haematology group (BSH OHG) and British 
Committee for Standards in Haematology (BSCH) do not 
share this position, recommending iron supplementation 
only in case of deficiency. 
The Polish Society of Gynecologists and Obstetricians 
shares this view. These recommendations result from the 
fact that, in recent years, it has been observed that there 
is a potential adverse effect of iron excess on the course of 
pregnancy and obstetric outcome. Iron takes part in the 
formation of reactive forms of oxygen and is responsible 
for development of insulin resistance and reduced insulin 
secretion by the pancreatic beta cells [11, 12]. Current re-
search indicates a possible link between iron excess and risk 
of preeclampsia, especially among women supplementing 
iron before 16 weeks of gestation with normal Hgb concen-
tration (Hgb > 13.2 g/dL at the beginning of the second 
trimester) [13–15]. 
In numerous studies, including two large meta-analyses, 
a correlation has been shown between the incidence of type 
two and gestational diabetes and the amount of iron stored 
in the body measured by iron concentration, hemoglobin 
and ferritin in blood serum [16–19]. 
Moreover, gestational diabetes has been shown to be 
more frequent in women supplementing iron that have nor-
mal hemoglobin levels [19, 20]. Helin et al. [21], showed that 
the occurrence of gestational diabetes was more frequent 
in a group of women with Hgb > 12 mg/dL with an aver-
age of 14.4 mg of iron in diet and an average of 27 mg in 
the form of Fe2+ supplements during preconception and 
in the first trimester. 
The total iron requirement in pregnancy is about 1–1.2 g, 
of which approx. 500–600 mg participate in the develop-
ment of pregnancy and the rest is the basic requirement 
of the body. 
According to literature reports, it can be concluded 
that women with iron supplies of about 500 mg, which cor-
responds to ferritin concentration of about 60–70 mcg/L, 
most likely will not develop anemia nor iron deficiency in 
pregnancy, despite the lack of supplementation [3].
Complete iron depletion from the reserve iron storage 
is evidenced by ferritin concentration < 12 mcg/L [5].
With ferritin level < 60 mcg/L in women without anemia, 
oral iron supplementation can be considered in small doses 
up to about 30 mg daily after 16 weeks of gestation, for 
a longer period of time, which is related to the availability 
of storage and transport proteins [22]. 
It is also important to be aware of other possible, anemia 
causes during pregnancy, like chronic diseases, infectios, 
B12 vitamin deficiency or malignant tumors.
Considering the above, an insightful analysis of the 
mean corpuscular volume of erythrocytes (MCV) and fer-
ritin concentration is recommended (Fig. 1), according to 
the diagram below. It allows appropriate implementation 
of dietary supplement with or without low dose iron (up 
to 30 mg) (Fig. 1).
Figure 1. Management of anemia in pregnancy
The blood count test is a basic element of standard pre-
natal care. Its assessment should not only be based on the 
analysis of hemoglobin or hematocrit levels, but also MCV 
levels, which is an inherent parameter of the result. During 
anemia diagnostic tests it is recommended to examine the 
level of ferritin, which determines the necessity of introduc-
ing therapeutic doses of iron. 
Summary
Taking into consideration the negative impact of both 
iron deficiency and excess on the course of pregnancy, ob-
stetric results and possible causes of anemia in pregnancy 
other than iron deficiency, it is recommended to:
1. Assess blood count and ferritin concentration at the first 
prenatal visit and then the blood count at 15–20, 27–32, 
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33–37 and 38–39 weeks of gestation (in accordance with 
the Standard Management of Physiological Pregnancy 
— a regulation of the Polish Minister of Health),
2. Use iron regimens before 16 weeks of gestation in wom-
en with iron deficiency anemia (with Hgb < 11 g/dL and 
low ferritin level),
3. Allow iron supplementation up to 30 mg daily in women 
without anemia with ferritin level below 60 mcg/L after 
16 weeks of gestation,
4. Use low oral doses of iron for longer period of time as 
treatment of iron deficiency anemia, and in the absence 
of improvement change to a preparation of higher prov-
en availability or increase the dose and further observe 
the Fe levels,
5. Analyze the necessity of packed red cells transfusion in 
case of no response to high therapeutic doses of oral 
iron or Hgb < 7 g/dL.
DOCOSAHEXAENOIC ACID (DHA)
Concentration of lipids (fats) in the human central nerv-
ous system is about 60% of its dry mass, which puts it in the 
second place of lipid concentration in human body, right 
after the adipose tissue.
Lipids are the structural core (building material) of all 
biological membranes surrounding cells of living organisms, 
which have a major impact on the structure of membranes, 
their fluidity and elasticity.
Scietific studies show that high DHA concentration in 
membrane phospholipids affects the function, survivability 
and plasticity of neurons, and its deficiency or slow me-
tabolism is certainly one of the causing factors of cognitive 
function decline, developing mental illnesses  or neurode-
generative diseases [23] and is important for neuron pro-
tection against apoptosis induced by oxidative stress [24].
All these characteristics of membranes increase their 
„dynamics” in comparison with membranes built from phos-
pholipids with a different building material [23]. 
An adequate DHA amount during pregnancy and lacta-
tion is therefore essential for preserving the proper devel-
opment at cellular and neural level, and in consequence 
ensuring proper visual acuity and normal psychomotor 
development of the child. It also reduces the risk of depres-
sion incidence in the mother [3, 22].
Fetal DHA requirement is significantly increased in the 
third trimester of pregnancy. In published research, includ-
ing meta-analyses, it was shown that omega-3 fatty acids 
supplementation reduces the risk of preeclampsia [25] and 
preterm birth [26–28]. 
In 2018 Olsen showed a 10-times higher risk of preterm 
birth before the 34 weeks of gestation in a group of women 
whose percentage of eicosapentaenoic acid (EPA) and DHA 
in the fatty acid pool was < 1.6% in comparison with women 
whose EPA and DHA percentage ≥ 1.8% (95% CI 6.80–15.79, 
p < 0.0001) [29].
Currently there are insufficient data to define target 
levels of DHA in blood serum, however the red blood cell 
(RBC) DHA level < 5% seems to have an effect of increasing 
the risk of preterm birth [29, 30].
The effect of omega-3 fatty acids on the reduction of 
the preterm birth risk is most likely the result of their an-
ti-inflammatory properties.
One of the mechanisms for developing uterus con-
tractions is the increase of connexin 43 and activation of 
myometrial receptors for oxytocin and prostaglandins. DHA 
stabilizes cell membranes by, i.e. modulation of Connexin 
43 expression.
EPA competes with arachidonic acid (ARA), which is 
a source of E2 and F2 alpha prostaglandins. 
The connection between consumption of fish and dura-
tion of pregnancy has been observed for many years, there 
are, however discrepancies in the recommended dose of 
polyunsaturated fatty acids.
Academy of Nutrition and Dietetics recommends sup-
plementation of 500 mg of DHA daily for women that con-
sume little amounts of fish, which is an equivalent of 2 por-
tions of wild pacific salmon. 
World Association of Perinatal Medicine recommends 
supplementation of at least 200 mg daily for all pregnant 
women [30]. 
Fish, algae and other seafood are a natural source of 
DHA, but one should keep in mind that fish can also be 
a source of environmental pollutants such as mercury, diox-
ins or polichlorinated biphenyls (PCBs). The highest levels of 
mercury are found in fish at the top of the food chain, such 
as shark, swordfish or tuna [31]. 
It seems justified that women at risk of DHEA deficiency, 
i.e. consuming low (lower than mentioned above) amount 
of fish, both during pregnancy and in the preconception 
period, should use polyunsaturated fatty acids in the form 
of supplements. 
It is not entirely clear if increasing the DHA dose up to 
600–1,000 mg daily brings benefits the further decline of 
the percentage of premature and very premature deliver-
ies (< 34 weeks of gestation), but it is known that DHA 
supplementation in doses up to 2,100 mg per day is not 
associated with any side effects neither for the pregnant 
woman nor the fetus) [30].
The DOMInO study involving 2,399 women in singleton 
pregnancies has shown that the incidence of very premature 
deliveries (< 34 weeks of gestation) was higher in a group 
of women using placebo in comparison to women consum-
ing 800 mg of DHA + 100mg of EPA per day (p = 0.03) [32].
In a multicenter Australian ORP study published in 2019, 
comprising of 5,486 women in singleton and multiple preg-
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nancies, taking not more than 150 mg of DHA daily, a rel-
evant statistical difference was not found in the incidence of 
very premature deliveries between women taking 900 mg of 
DHA per day additionally and a group of women also using 
vegetable oil containing only small amounts of DHA [33]. 
Currently the ADORE study is conducted in a group of 
900–1,200 women and aims to compare the incidence of 
very premature deliveries in groups of pregnant women 
supplementing 200 and 1,000 mg of DHA per day. The study 
is expected to be completed in 2021[34]. 
Perhaps it will allow for determining the optimal dose 
of DHA supplementation in pregnancy.
Summary
Considering all available knowledge about DHA impact 
on the course of pregnancy and obstetric outcomes, it is 
currently recommended to: 
1. Supplement at least 200 mg of DHA in all pregnant 
women,
2. Consider using higher doses of DHA in women consum-
ing small amounts of fish during pregnancy and in the 
preconception period,
3. Use 1,000 mg of DHA daily in the group of women at 
risk of premature birth.
VITAMIN D
Vitamin D is a group of fat-soluble steroidal organic 
compounds. Two forms of vitamin D differing in the struc-
ture of the side chain are the most relevant ones: vitamin 
D2 (ergocalciferol) supplied to the human body with yeast 
and plant food and vitamin D3 (cholecalciferol) supplied 
with food of animal origin and produced in the skin under 
the influence of UV radiation [35].
Both D2 and D3 vitamins have no biological activity. 
It is only obtained through hydroxylation, which results in 
the formation of 1α, 25-dihydroxyvitamin D. The activation 
process takes place successively in the liver and then the 
kidneys, where both active forms of vitamin D2 and D3 [1α, 
25-(OH) 2D2 and 1α, 25-(OH) 2D3] of identical biological 
properties are ultimately formed [36].
The role of vitamin D in regulating calcium and phos-
phorus levels in blood serum, maintaining the correct bone 
mineral density and its modulating effect on the function of 
the immune system has been commonly known. It cannot 
be ruled out that vitamin D deficiency may also play a role 
in the incidence of recurrent miscarriages, especially those 
of unspecified etiology [2]. 
Most randomized controlled trials have shown a positive 
effect of vitamin D on the course of pregnancy, however 
only when supplementation was started during placenta-
tion [37]. A precise effect of vitamin D on the process of 
placentation has not yet been explained. 
It is known that 1.25(OH)2D affects the HOXA10 gene 
expression, responsible for uterine development in fetal 
life, development of endometrium, implantation and the 
trophoblast invasion into decidua [38].
A meta-analysis of 22 studies (consisting of 3,725 wom-
en in total) has indicated, that vitamin D supplementation in 
pregnancy in comparison with placebo, probably reduces 
the risk of preeclampsia [risk ratio (RR) 0.48, 95% confidence 
interval (CI) 0.30–0.79; 4 studies, 499 women], gestational 
diabetes (RR 0.51, 95% CI 0.27–0.97; 4 studies, 446 women) 
and LBW (< 2,500g) (RR 0.55, 95% CI 0.35–0.87; 5 studies, 
697 women). 
It is likely that vitamin D supplementation also reduces 
the risk of postpartum hemorrhage (RR 0.86%, 95% CI 0.51–
–0.91; 1 study, 1,134 women) [39]. Another meta-analysis 
comprising of 16 studies, 28,285 women in total, has shown 
a relationship between vitamin D deficiency in pregnancy 
and the incidence of SGA [40]. 
However, it should be emphasized that some of the 
quoted studies were not randomized. 
The most relevant source of vitamin D for the hu-
man body is its synthesis through the skin. In Poland it 
is possible only from March to September and requires 
an exposure lasting at least half an hour without the use of 
sunscreen with UV filters [22]. Polish data, however, indicate 
a significant vitamin D deficiency in newborns regardless of 
the season when they were born [41]. 
In studies conducted in a group of pregnant women 
from the USA, Northern Europe and the Middle East it has 
been shown that 26–90% of them have vitamin D deficiency, 
defined as 1.25(OH)2D concentration < 50 mmol/ L [2]. 
Women with BMI > 30 are at particularly high risk of vi-
tamin D deficiency. It is believed that their diet does 
not contain or contains not enough vitamin D. In most 
European countries and in the USA, supplementation 
of at least 600 IU of vitamin D per day is recommended. 
It is recognized that a dose of 1,500–2,500 IU in pregnancy 
and lactation could keep the vitamin D concentration in 
blood serum > 75 nmol/L. In most pregnant women it largely 
depends on their general health condition, individual diet 
and overall life hygiene. Choosing the correct dose of the 
supplement would be much easier after performing a blood 
test determining its actual concentration in the serum. Most 
often, for practical reasons for the purposes of laboratory 
diagnostics, the combined concentration of 25-OH-D2 and 
25-OH-D3 is determined [42]. 
However, these tests go far beyond the standard perina-
tal care and are sometimes used for clinical trials developing 
conclusions disseminated later in recommendations. 
The studies conducted so far have not shown any adverse 
effect of vitamin D supplementation in pregnancy up to 
4,000 IU per day [37]. Assessment of vitamin D serum con-
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centration in pregnant women would allow for selection of 
an individual dose which is particularly important in group 
of women at higher risk of 1.25(OH)2D deficiency, i.e. obese, 
with liver or kidney disease, chronic intestinal and thyroid 
gland diseases, or with diabetes, using antiepileptic or antiret-
roviral drugs [43]. Perhaps it would also allow for variation of 
the recommended dose in individual deficiency risk groups. 
Summary
According to the current knowledge, it is recommended to:
1. Supplement 1,500–2,000 IU of vitamin D per day dur-
ing pregnancy and lactation in women without factors 
suggesting vitamin D deficiency,
2. Adjust the vitamin D dose in pregnant women to its 
levels in the blood serum (optimal treatment),
3. Consider doses up to 4000 IU per day in women with 
high body mass index (BMI) > 30 kg/m2 [44].
IODINE
During pregnancy the requirement for iodine increases, 
which is related to its loss through kidneys, deiodinase activ-
ity and fetal demand [22], however, the recommendations 
for supplementation of this element in pregnancy differ 
depending on the world region and the level of its deficiency 
in a given population. Significant iodine deficiency can be 
a cause of hypothyroidism in both pregnant woman and 
fetus, disorders of nerve myelination, CNS damage, mental 
retardation, hearing loss and deafness in newborns, as well 
as an increased risk of miscarriage and preterm deliveries.
However, such correlation was not observed in cases of 
mild and moderate deficiency i.e. with UIC (Urinary Iodine 
Concentration) in the range of 50–150 mcg/L [45, 46].
Iodine supplementation during the preconception pe-
riod and in early pregnancy may reduce the risk of mental 
retardation of a newborn. 
Despite the introduction of the WHO-recommended 
salt iodization programme, Europe still remains a region of 
iodine deficiency, with only 66% of children of school age 
having its adequate level. One should keep in mind that 
the requirement for iodine in pregnant women is approx. 
1.5 times higher. In 2/3 of European countries, including 
Poland, it has been found that the median iodine level in 
pregnant women is below the norm, meaning that at least 
50% of pregnant women in Poland suffer from iodine de-
ficiency [47]. 
The best sources of iodine in diet are dairy products, 
eggs, fish and iodized salt. For women avoiding dairy prod-
ucts because of intolerance or by choice, or those limit-
ing the intake of salt, providing a sufficient iodine supply 
without its supplementation is usually difficult to achieve. 
It should also be mentioned that one of the elements 
that relatively easily displaces iodine from the organism 
is fluorine, commonly added to drinking water in many 
countries.
Numerous scientific studies directly point out the cor-
relation between excessive consumption of this element 
and hypothyroidism, therefore an increased fluorine intake 
has an effect on elevated TSH levels. Hence, it is necessary in 
many cases to introduce iodine supplementation and target 
the consumption of mineral or spring water containing no 
controversial fluorine [48].
On the other hand, it should not be forgotten that an ex-
cess of iodine can cause thyroid function disorders, in the 
form of both hyperthyroidism and hypothyroidism, espe-
cially in women with anti-thyroid antibodies. Acute iodine 
poisoning may lead to gastrointestinal disturbance, cardiac 
disorders or even coma [45].
The publication made by Zhou and Condo has shown 
impaired psychomotor development of children at 
18 months of age, assessed on the Bayley-III scale, both 
in case of supplementing too low (< 220 mcg/day) and 
too high (> 391 mcg/day) iodine doses before 20 weeks 
of gestation [49]. 
An ideal way to adjust the iodine dose to the needs of 
the individual pregnant women would be measuring the 
levels of anti-thyroid antibodies, thyroid hormones and renal 
iodine clearance, which should increase from 150 mcg/L up 
to 249 mcg/L during pregnancy. Abnormal TSH, fT3 and 
fT4 serum levels reflect thyroid dysfunction, while elevated 
thyroglobulin (Tg) level is an indirect indicator of iodine de-
ficiency and iodine concentration in urine (UIC) > 499 mcg/L 
indicates its excessive intake [45].
Considering the difficulties in performing the above 
tests on a regular basis, the average requirement for iodine 
in pregnant women has been estimated in various regions 
of the world and the recommended dose of supplementa-
tion in pregnancy ranges from 150 mcg/day in Australia and 
New Zealand, 200 mcg/day in the European Union countries 
(EFSA) [50] to 220 mcg/day in the USA [2].
The maximum safe dose of iodine in the general popula-
tion, which does not seem to cause adverse effects in healthy 
pregnant women, has been accepted to be 600 mcg/day in 
the EU countries and 1,100 mcg/day in the USA [45]. How-
ever, these doses seem too high because of high incidence 
of thyroid gland diseases in these areas [2].
Summary
In light of the latest research it is recommended to:
1. Supplement iodine in all pregnant women with no his-
tory of thyroid gland disease at a dose of 150–200 mcg 
per day,
2. Supplement iodine in women with thyroid gland disease 
while controlling thyroid hormones and the concentra-
tion of anti-thyroid antibodies.
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FOLIC ACID
Folate participates in a number of chemical reactions 
responsible for transferring carbon units (OCM, one carbon 
metabolism), which consists of: folate transformations, ho-
mocysteine methylation and transsulfuration. These reactions 
play a key role in the synthesis of nucleic acids, proteins, reac-
tive forms of oxygen and epigenetic regulation [51] (Fig. 2).
Homocysteine is an amino acid synthesized in all body 
cells from an exogenous amino acid — methionine, de-
rived mostly from animal proteins. In the above homocyst-
eine-methionine pathway, folic acid is involved (Fig. 3). Its 
deficiency may lead to hyperhomocysteinemia, defined as 
serum homocysteine concentration > 15 mcmol/L. 
The main role of homocysteine is to rebuild damaged 
tissue, though it should not be forgotten that it also exhibits 
prothrombic properties.
Hyperhomocysteinemia, which occurs with folate defi-
ciency can carry a number of adverse effects in homeostasis 
of both pregnant woman and the fetus. An elevated serum 
homocysteine concentration is considered to be a risk factor 
for development of many diseases, especially of the cardio-
vascular system and indirectly of dementia, as a result of 
atherosclerosis development in the cerebral vessels [51, 52]. 
It may also have an adverse effect on the course of preg-
nancy, impairing the blood supply to the placenta, which 
may lead to fetal growth restriction (FGR) or intrauterine 
death, as well as a negative impact on the development of 
the CNS of the fetus [51].
An excessive consumption of animal proteins causes 
temporary increase in serum homocysteine levels. However, 
there is no convincing evidence that an increased methio-
nine intake causes chronic elevation of homocysteine, es-
pecially in people with proper B vitamins intake, including 
folic acid. An unbalanced diet is a common cause of increase 
in homocysteine concentration, including vegetarian and 
vegan diets, with no additional, yet in this case, necessary 
supplementation of folic acid and other vitamins, especially 
the B complex. Modern food processing can also lead to 
a breakdown of a significant percentage (30–55%) of es-
sential vitamins [53].
It is important to remember about other relevant causes 
of hyperhomocysteinemia, such as liver or kidney failure, 
diabetes, malignant tumors or using drugs like methotrex-
ate (which inhibits dihydrofolate reductase), metformin 
(which affects the metabolism of B12 vitamin), cholesty-
ramine (which reduces the absorption of B12 and folate), 
carbamazepine and valproic acid (which affect the folic 
acid metabolism), stimulants and genetically determined 
deficiency or lack of enzymes involved in homocysteine 
metabolism, especially of the cystathionine β-synthase (oc-
curring 1/200–400 000 births) [53].
In recent years, possible contribution of another enzyme 
involved in folic acid metabolism and therefore homocyst-
eine was pointed out — 5, 10-reductase methylenetet-
rahydrofolate (MTHFR). It is believed, that MTHFR activity 
can be moderately reduced in cases of commonly occurring 
polymorphic variants c.665C > T (known so far as c.677C > T) 
and c.1298A > C in the MTHFR gene (NM_005957). They are 
particularly common in white and Caucasian race, also in 
Poland, reaching up to 50% of general population. 
Currently, however, there is no sufficiently documented 
evidence indicating significant impact of the mentioned 
variants on the incidence of high homocysteine concen-
tration or neural tube defects [54]. There is no indication 
to use higher doses of folic acid or its active form in these 
cases. Considering the inverse correlation between ho-
mocysteine and folic acid serum levels it has been estab-
lished that folic acid concentration > 10 nmol/L in blood 
serum and > 349 nmol/L in erythrocytes reflects its suf-
ficient consumption in a healthy adult population. Based 
on randomized studies it has been established that daily 
requirement for folates, in this group, allowing for main-
tenance of the proper concentration in blood is 400 mcg, 
including 250 mcg for natural folates and 150 mcg for folic 
acid, respectively. To achieve the same level of folate in 
erythrocytes, pregnant women require an intake of about 
600 mcg in the II and III trimesters, and about 500 mcg daily 
during lactation [50]. 
Figure 2. The effect of folic acid on homeostasis [51]
Figure 3. Homocysteine metabolism pathway [51]; 1 — methionine 
adenosyltransferase; 2 — methionine synthase; 3 — reductase 5, 
10-methylenetetrahydrofolate (MTHFR); 4 — betaine-homocysteine 
methyltransferase; 5 — cystathionine βsyntase; 6 — γ-cystathionase [53]
650
Ginekologia Polska 2020, vol. 91, no. 10
www. journals.viamedica.pl/ginekologia_polska
Folate deficiency can also result in impaired DNA syn-
thesis and cell division, especially in rapidly growing tissues 
like bone marrow or fetal tissues. As a result of folic acid defi-
ciency erythrocytes may form an abnormal nucleus, megalo-
blastic anemia as well as miscarriages and birth defects may 
develop, especially neural tube defects, which incidence is 
globally estimated at about 18.6/10,000 births [55].
Although the etiology of neural tube defects is multi-
factorial and both genetic and environmental factors take 
part in their formation, it is now known that one carbon 
metabolism plays a significant role in the process of neural 
tube closure. Mutations in genes coding enzymes participat-
ing in the OCM pathways are most certainly associated with 
the risk of natural tube defects (NTD) incidence.
However, despite of 30 years of research on genes in-
volved in the process of neural tube closure, no simple 
correlation between mutations in specific genes and the 
incidence of NTD was found. Research carried out in the 
recent years indicate that the underlying cause of neural 
tube defects is polygenic and the risk of their occurrence 
increases with the accumulation of various mutations [55].
Neural tube closure occurs within 28 days after concep-
tion. Abnormalities in the course of this process result in 
formation of defects, such as anencephaly or spina bifida.
In 90% of cases, spina bifida is accompanied by type II 
Arnold-Chiari malformation, which involves displacement 
of the hindbrain structures to the spinal canal. 
The correlation between folate deficiency and the in-
cidence of NTD was discovered in 1965. CDC followed by 
issuing a recommendation in 1991 that women with prior 
NTD child should supplement 4 mg of folic acid per day 
for a strictly defined time, i.e. at least 4 weeks before the 
pregnancy and during its first 12 weeks. The recommen-
dation was based on a research conducted on a group of 
1,195 women with a history of NTD, in which the incidence 
of NTD in the next pregnancy was compared in a group of 
women using 4 mg of folic acid and in a folate-free group, 
finding a reduction of the NTD risk from 3.5% to 1% with 
no adverse effects [56]. 
Prolonged use of 4mg/d of folic acid may have potential-
ly harmful effects on the fetus. A research by Johns Hopkins 
Bloomberg School of Public Health has shown that supple-
menting high doses of folates in pregnancy may increase 
the risk of autism in children. Due to the above report, in 
2016 RCOG recommended using higher than 400 mcg/d 
doses of folic acid only in strictly defined groups of pregnant 
women and not longer than until 12 weeks of gestation [57]. 
In 2008, a study consisting of 700 women in India, Yajka 
and Deshpande showed possible effect of high folic acid con-
centration in erythrocytes of women at 28 weeks of gestation 
on the risk of developing insulin resistance in their offspring, 
measured by the HOMA-R index in 6-year-old children.
Excess of folic acid can also mask first symptoms of vi-
tamin B12 deficiency-megaloblastic anemia [59, 60]. There 
have also been studies showing that using lower doses of 
folic acid for a longer period of time is effective in prophy-
laxis of neural tube defects [61–65].
However, selection of population groups in the above 
research does not authorize a change in the currently ad-
vocated use of 4 mg of folic acid in a group of patients with 
a history of NTD at least 4 weeks before planned conception 
and first 12 weeks of pregnancy. 
Is should be remembered that although maternal folate 
deficiency may cause neural tube defects in the fetus, most 
NTDs occur in children whose mothers had normal levels 
of folic acid in blood serum. Exogenous folic acid prevents 
some neural tube defects most probably by epigenetic 
regulation (methylation) and regulation of cell division (pu-
rine synthesis).
Relevant environmental risk factors for NTD in-
clude: pregestational diabetes (risk 2–10 times higher), 
BMI > 30 (risk 1.4–3.5 higher), use of antiepileptic drugs 
(carbamazepine and valproic acid are associated with 1–2% 
of NTD risk), genetic conditions- neural tube defects in previ-
ous pregnancy or in a family history [66–70].
Serum folate level increases right after consumption 
and the effect lasts briefly, while the level in erythrocytes 
reflects the stored amount in the body better. 
It has been shown that at RBC folate concentration of 
1,000–1,300 nmol/L the risk of NTD is 7.9/10,000 pregnan-
cies. Further increase of folate concentration in erythrocytes 
did not significantly reduce the risk [66] (Fig. 4).
In 1998, the FDA recommended fortifying foods with 
folic acid. Adding a dose of 0.4 mg of folate per 100 g to 
basic products (bread, pasta, flour) allowed an increase in 
the daily intake from 0.288 ± 195 mg to 0.550 ± 279 mg, 
which resulted in a decline of NTD incidence from 6.86 to 
4.04/10,000 pregnancies. The above food enrichment was 
also introduced by countries like Canada, South Africa Chile, 
Saudi Arabia with a similar result. 
In the EUROCAT study including 34 studies from 8 Euro-
pean countries where no food fortification was introduced 
and only supplementation of folic acid in preconception 
and early pregnancy was used between 1980 and 2001, 
such relevant reduction of NTD incidence was not obtained. 
The incidence of neural tube defects in those countries 
was 9.1/10,000 pregnancies. Furthermore, the research has 
indicated that folate supplementation in the preconception 
period does not exceed 50%. Though one should keep in 
mind that about 60% of all pregnancies is unplanned!
A 2017 in Germany study in a population of healthy, 
non-pregnant women, excluding women with diabetes, 
BMI > 30 or with chronic gastrointestinal diseases result-
ing in malabsorption such as colitis ulcerosa, Crohn’s or 
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celiac disease, has shown that 88% of them have folate 
concentration in RBC <906 nmol/l, 6% < 340 nmol/L, and 
the mean folate concentration was 640 nmol/L. Folic acid 
supplementation in a dose of 0.8 mg/d for 4 weeks allow 
for folate concentration in RBC > 906 nmol/L in 45%, while 
supplementation of 0.04 mg/d in the same period of time 
allowed for reaching > 906 nmol/L in only 31% of respond-
ents. Extending the supplementation period to 8 weeks 
obtained the required dose in 83% of the 0.8 mg/d dose 
group and in 54% of the 0.4 mg/d dose group, respectively. 
In a 2019 meta-analysis it has been shown that sup-
plementation of 0.4 mcg/d of folate for about 36 weeks 
increases the folate levels in RBC by about 78% compared 
to the initial baseline and maintaining this concentration 
with further supplementation with the same dose, while 
the higher the increase, the lower the initial concentration. 
For example, in case of folate concentration in RBC at 
600 nmol/L, a 400 mcg/d dose causes an increase in folate 
concentration in RBC to 1,065 nmol/L within 9 months [72]. 
In a 2019 recommendation for food producers, the FDA 
established the optimal daily dose of consumed folate in the 
form of fortified food for the general population as 0.4 mg/d, 
0.8 mg/d during pregnancy and lactation and the safe upper 
limit was established to be 1 mg [73]. 
In 2019 EFSA recommended the daily folate consump-
tion to be 0.33 mg/d in a population of healthy men and 
non-pregnant women, 0.6 mg/d for pregnant women and 
0.5 mg/d for breastfeeding women.
According to current research, the best solution to pre-
vent the neural tube defects seems to be obligatory fortifi-
cation of food with folic acid, which also is an appeal of the 
Polish Society of Gynecologists and Obstetricians. 
The CDC and Institute of Medicine recommend that all 
women of reproductive-age intake at least 0.4 mg/d of folic 
acid in form of supplements, fortified food or the combination 
of both as an addition to a natural, folate-rich diet [56, 74].
Summary
According to the up-to-date knowledge, it is recom-
mended to:
1. Use 0.4 mg/d of folic acid in all women of reproductive 
age, as a supplement to natural, folate-rich diet,
2. Supplement 0.4–0.8 mg/d of folic acid in the first trimes-
ter (before 12 weeks of gestation),
3. Supplement 0.6–0.8 mg/d of folic acid after 12 weeks of 
gestation and during lactation in a population of women 
with no additional risk factors,
4. Supplement 4 mg/d of folic acid in women with history 
of NTD in prior pregnancy, in a strictly defined period 
of time, i.e. at least 4 weeks before planned conception 
and during the first 12 weeks of pregnancy, then reduc-
tion of the dose to the levels of the general population,
5. Use 0.8 mg/d of folate for at least 3 months before 
planned conception and during pregnancy and lacta-
tion in women with high risk of folate deficiency and 
NTD:
•	 with type I or II diabetes before pregnancy,
•	 use of antiepileptic drugs, methotrexate, cholesty-
ramine, metformin, sulfadiazine before or during 
pregnancy,
Figure 4. Red blood cell dependent risk of natural tube defects
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•	 using stimulants,
•	 with liver or kidney failure,
•	 with BMI > 30,
•	 after bariatric surgery or with gastrointestinal dis-
eases resulting in malabsorption (Crohn’s disease, 
colitis ulcerosa, celiac disease).
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